Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
GRAFT-REJECTION AND RECOVERY OF HOST-DERIVED HEMATOPOIESIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - RELATION TO CONDITIONING WITH HIGH-DOSE ETOPOSIDE AND TOTAL-BODY IRRADIATION
Autore:
HARA M; SHINAGAWA K; OMOTO E; SUNAMI K; DEGUCHI S; NARUMI H; KOJIMA K; AZUMA T; TAKAMATSU H; NAKAO S; HARADA M;
Indirizzi:
EHIME PREFECTURAL CENT HOSP,DIV HEMATOL,83 KASUGAMACHI MATSUYAMA EHIME 7900024 JAPAN
Titolo Testata:
International journal of hematology
fascicolo: 1, volume: 68, anno: 1998,
pagine: 95 - 100
SICI:
0925-5710(1998)68:1<95:GAROHH>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
VARIABLE NUMBER; AMPLIFICATION; FAILURE;
Keywords:
GRAFT REJECTION; TBI/VP-16 REGIMEN; HOST-DERIVED HEMATOPOIESIS; ALLOGENEIC BMT; ETOPOSIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
8
Recensione:
Indirizzi per estratti:
Citazione:
M. Hara et al., "GRAFT-REJECTION AND RECOVERY OF HOST-DERIVED HEMATOPOIESIS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - RELATION TO CONDITIONING WITH HIGH-DOSE ETOPOSIDE AND TOTAL-BODY IRRADIATION", International journal of hematology, 68(1), 1998, pp. 95-100

Abstract

Engraftment failure following allogeneic bone marrow transplantation (BMT) is ran in patients with acute leukemia, after frequent conditioning with marrow-lethal chemoradiotherapy. We evaluated the efficacy ofa preparatory regimen consisting of fractionated total body irradiation (TBI) (12 Gy in six fractions) and high dose etoposide (60 mg/kg) administered as an 8-h infusion for allogeneic BMT in 16 consecutive patients with acute leukemia. Although 14 patients showed complete and sustained engraftment, the remaining two patients rejected bone marrow grafts from HLA-identical sibling donors and showed subsequent recovery of host-derived hematopoiesis. Despite the limited number of patients, this observation suggests that the immunosuppressive potential of etoposide may be inferior to that of cyclophosphamide (CY) and that etoposide as an alternative to CY as an antileukemic and immunosuppressive agent in allogeneic BMT may increase the risk of graft rejection. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 14:15:30